Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice?

Journal of Rheumatology

Volumn 33, Issue 7, 2006, Pages 1243-1246

  Soubrier, Martin ^a   Zerkak, Djamila ^b   Gossec, Laure ^b   Ayral, Xavier ^b   Roux, Christian ^b   Dougados, Maxime ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Disease activity; Disease activity score 28; Rheumatoid arthritis; Simplified disease activity index

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DECISION MAKING; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; PAIN ASSESSMENT; PATIENT GLOBAL ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RHEUMATOLOGY; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 33745794037     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004;63:627-33.
2. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
3. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology Oxford 2003;42:244-57.
4. Fransen J, Welsing PMJ, De Keijzer RMH, Van Riel PLCM. Disease activity scores using C reactive protein: CRP may replace ESR in the assessment of RA disease activity [abstract]. Ann Rheum 2003;62 Suppl 1:Thu0138.
5. Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis. Defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
6. Pham T, Gossec L, Fautrel B, et al. Clinical and biological evaluation in the management of patients with rheumatoid arthritis: recommendations for clinical practice based on published data and expert opinions (discussions among rheumatology experts). Rev Rhum 2004;71:S127-S136.
7. Soubrier M, Zerkak D, Dougados M. Indications for LDL cholesterol lowering interest in rheumatoid arthritis (RA): an underestimated prevalence [abstract]. Arthritis Rheum 2004;50 Suppl:S379.
8. Welsing PMJ, Landewé RBM, van Riel PLCM, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis. A longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
9. Grigor C, Capell H, McMahon A, Vallance R, Kincaid W, Porter D. Effect of a treatment of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
10. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The DAS score is not suitable as the criterion for TNF initiation in the clinic: evidence of disagreement between physician and patient assessments and DAS scores [abstract]. Arthritis Rheum 2004;50 Suppl:S459.
11. Wolfe F, Michaud K, Furst DE, Keystone E. Differing valuations of disease activity according to DAS score and patient and physician ratings: implications for clinical trials and clinical care. Ann Rheum Dis 2004;63 Suppl 1:200.
12. Stenger AAME, van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
13. Delving J, Gough A, Huissoon A, et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1997;24:9-13.
14. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technology appraisal no. 36. London: NICE; March 2002. [Internet. Available from http://www.nice.org.uk/pdf/RA-PDF.pdf] Accessed March 5, 2006.